Market Scenario

Global Organoids and Spheroids Market was valued at US$ 771.4 million in 2022 and is projected to attain a valuation of US$ 4,567.0 Million by 2031 at a CAGR of 22.42% During the Forecast Period 2023-2031. 

The global organoids and spheroids market is rapidly expanding and expected to continue growing due to increasing demand for personalized medicine, efficient drug discovery, and rising chronic diseases prevalence. Organoids and spheroids, which are three-dimensional structures derived from stem cells, are utilized for drug discovery, disease modeling, and regenerative medicine. Personalized medicine demand has increased to customize medical treatment based on genetic makeup. Organoids and spheroids are used to create patient-specific disease models to develop customized treatment plans. Organoids and spheroids have become an alternative to traditional drug discovery methods, which are time-consuming, costly and often fail to predict how a drug will perform in the human body. 

Organoids and spheroids offer a more accurate representation of how drugs will interact with human tissues, speeding up the drug discovery process and reducing costs. The rise of chronic diseases, such as cancer, diabetes, and heart disease, has led to organoids and spheroids being developed for new treatments and therapies. 

The market is fragmented, with small and medium-sized companies operating, but major players are developing new and innovative organoid and spheroid technologies, expanding their product portfolios through partnerships and collaborations. The market is expected to continue expanding, with organoids and spheroids increasingly utilized in regenerative medicine for a variety of conditions such as liver disease, kidney disease, and neurodegenerative disorders.

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Increasing Demand for Personalized Medicine

The increasing demand for personalized medicine is one of the major drivers behind the growth of the organoids and spheroids market. Personalized medicine refers to the customization of medical treatment based on an individual's unique genetic makeup, lifestyle, and environment. With the advancements in genetic sequencing technologies and bioinformatics, it has become easier and more affordable to identify genetic variations that are associated with different diseases. Organoids and spheroids are used in personalized medicine to create patient-specific models of diseases, which can help doctors to develop customized treatment plans.

One of the main benefits of using organoids and spheroids in personalized medicine is the ability to test different drugs on patient-specific disease models before administering them to the patient. This helps to identify the most effective treatments for each patient and reduces the risk of adverse reactions. Organoids and spheroids can also be used to monitor disease progression and to assess the effectiveness of different treatments over time.

Using organoids and spheroids in personalized medicine offers the ability to study the underlying mechanisms of diseases in a more accurate and comprehensive manner. Organoids and spheroids can be used to study the genetic and cellular changes that occur during disease development, which can help to identify new drug targets and therapeutic approaches.

Growing Need for Efficient and Effective Drug Discovery

The organoids and spheroids market is being driven by the need for more efficient and effective drug discovery. The traditional methods of drug discovery are often expensive and time-consuming, and they often fail to accurately predict how a drug will interact with human tissues. However, organoids and spheroids provide a more accurate representation of how drugs will interact with human tissues, reducing the time and cost of drug discovery.

Organoids and spheroids are being increasingly used to identify potential drug candidates more quickly and efficiently. These three-dimensional structures derived from stem cells can be used to screen large numbers of compounds for their ability to affect specific cellular pathways or disease processes. This helps to identify the most promising drug candidates, which can then be further tested in animal models and eventually in human clinical trials.

Moreover, organoids and spheroids are also being used as alternatives to animal models, which can help to reduce the number of animals used in drug testing and increase the ethical standards of drug development. As a result, the use of organoids and spheroids in drug discovery is gaining popularity in the pharmaceutical industry.

The organoids and spheroids market is expected to grow rapidly in the coming years due to increasing demand for more efficient and effective drug discovery methods. Major pharmaceutical companies are investing heavily in organoid and spheroid technology, which is expected to drive the market growth further. Additionally, organoids and spheroids are being developed for various therapeutic areas such as oncology, neurology, and regenerative medicine. As the market continues to evolve, there will be more innovative applications of organoids and spheroids in drug discovery, resulting in faster and more cost-effective drug development.

Restrain 

Ethical and Regulatory Concerns

The growth of the organoids and spheroids market is restrained by the ethical and regulatory concerns surrounding the use of stem cells. The use of stem cells in organoids and spheroids production raises ethical issues related to the origin of the cells, their use, and their potential impact on human health. These concerns have led to the development of complex regulatory frameworks, which can lead to delays in the approval process and increased costs.

Furthermore, the use of organoids and spheroids in drug discovery and personalized medicine raises concerns over privacy and data protection. The patient-specific models of diseases created using organoids and spheroids can contain sensitive genetic information, which must be protected to ensure patient confidentiality.

To address these concerns, there is a need for greater clarity and standardization in the ethical and regulatory framework surrounding the use of stem cells and organoids/spheroids. Collaboration between government agencies, industry leaders, and ethical experts is essential to develop clear guidelines and best practices for the use of stem cells in organoids and spheroids production. Such efforts could increase transparency and promote public trust in the technology, which could, in turn, stimulate further growth in the organoids and spheroids market.

Segmental Analysis 

By Type:

The organoids segment is expected to generate more than 53% of the revenue in the global organoids and spheroids market. This can be attributed to the increasing use of organoids in drug discovery, disease modeling, and personalized medicine. Organoids are three-dimensional structures that are derived from stem cells and can be used to create patient-specific models of diseases, which can help in the development of customized treatment plans.

On the other hand, spheroids are being used primarily in drug discovery and development, as they can provide a more accurate representation of how drugs will interact with human tissues. Spheroids are expected to see steady growth due to their increasing use in drug screening assays.

By Application:

The developmental biology segment is expected to generate over 33% of the market share in the global organoids and spheroids market. This is due to the growing demand for organoids and spheroids in studying organ development and tissue regeneration. Developmental biology is a rapidly evolving field, and organoids and spheroids are being used to model complex developmental processes such as organogenesis, which can provide valuable insights into the mechanisms underlying developmental disorders.

In addition to developmental biology, organoids and spheroids are being used in various other applications such as disease modeling, drug discovery, and regenerative medicine, which are expected to see significant growth in the coming years.

By End User:

The pharmaceutical and biotechnology industry segment is expected to dominate the global organoids and spheroids market, accounting for over 50% of the revenue share by 2031. This is due to the increasing demand for efficient and effective drug discovery, as well as the rising prevalence of chronic diseases. Organoids and spheroids are being used to develop new treatments and therapies for chronic diseases such as cancer, diabetes, and heart disease.

Academic and research institutes are also expected to see significant growth in the organoids and spheroids market due to their increasing use in developmental biology research and disease modeling. The contract research organizations (CROs) segment is also expected to see significant growth due to the increasing outsourcing of drug discovery and development services by pharmaceutical and biotechnology companies.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America is holding over 40% market share and its dominance in the organoids and spheroids market can be attributed to several factors, including the presence of key market players, favorable government initiatives, and increasing research activities in the region. The strong presence of companies such as Thermo Fisher Scientific and STEMCELL Technologies has enabled the region to offer a wide range of innovative and advanced organoid and spheroid technologies, further strengthening its market position.

The favorable government initiatives and regulations in North America, such as the investments made by the National Institutes of Health in stem cell research, have contributed significantly to the growth of the organoids and spheroids market. This has led to increased funding for stem cell research, which has propelled the growth of the market in the region.

Moreover, North America's increasing research activities have been driving the growth. The region has some of the leading research institutions and academic centers, which are at the forefront of organoid and spheroid research. These institutions have been successful in developing advanced organoid and spheroid technologies, which have further fueled the market growth.

As a result of these factors, North America is expected to continue dominating the organoids and spheroids market in the foreseeable future. The region's strong presence of market players, favorable government initiatives, and increasing research activities are likely to contribute to further innovation and technological advancement in the field of organoids and spheroids, leading to the continued growth of the market.

List of Key Companies Profiled:

• 3D BioMatrix
• 3D Biotek LLC
• AMS Biotechnology (Europe) Limited
• ATCC
• Cellesce Ltd
• Corning Incorporated
• Greiner Bio-One
• Hubrecht Organoid Technology (HUB)
• InSphero/Perkin Elmer
• Kuraray
• Lonza
• Merck KGaA
• Prellis Biologics
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific, Inc.
• Other Prominent Players.

Recent Developments:

• February 2020: PerkinElmer, a global leader in health science and innovative detection solutions, introduced its new workstations and the Opera Phenix Plus high content screening system at SLAS2020 in San Diego. The system is designed to boost productivity, improve repeatability, and provide deeper insights for professionals in disease research and drug discovery. The Opera Phenix Plus system's compatibility with diverse cell cultures, 3D organoids, spheroids, and microtissues allows for more relevant testing early in the drug development process.
• March 2022: Cellesce, a biotechnology company specializing in the expansion of organoids, was granted its first patent family (EP 3 481 942 B1). The patent is expected to be granted globally, including in the USA, China, and Japan. This patent validates Cellesce's ownership of a unique process for manufacturing organoids at an industrial scale while maintaining the high-quality standards necessary for commercial deployment of organoids.
• March 2022: Greiner Bio-One, a leading company in the production of sample and assay technologies, has developed new variants of its CELLdisc product, featuring closed filling lids to ensure the highest sterility protection levels in strictly regulated environments. The lids, made from USP Class VI approved silicone tubes, are connected to the CELLdisc screw cap and can be securely linked to liquid reservoirs such as media bags. The entire disposable unit, which comes preassembled with the appropriate CELLdisc, is sterilized as a single piece, ensuring optimal sterility, system integrity, and convenience.

Market Segmentation Overview

By Type

• Organoids
  • Neural Organoids
  • Hepatic Organoids
  • Intestinal Organoids
  • Kidney Organoids
  • Other Organoids
• Spheroids
  • Multicellular tumor spheroids (MCTS)
  • Neurospheres
  • Mammospheres
  • Hepatospheres
  • Embryoid bodies

By Method

• Organoids
  • General Submerged Method for Organoid Culture
  • Crypt Organoid Culture Techniques
  • Air Liquid Interface (ALI) Method for Organoid Culture
  • Clonal Organoids from Lgr5+ Cells
  • Brain and Retina Organoid Formation Protocol
• Spheroids
  • Micropatterned Plates
  • Low Cell Attachment Plates
  • Hanging Drop Method
  • Others

By Source 

• Organoids
  • Primary Tissues
  • Stem Cells
• Spheroids
  • Cell Line
  • Primary Cell
  • iPSCs Derived Cell

By Application

• Developmental Biology
• Personalized Medicine
• Regenerative Medicine
• Disease Pathology Studies
• Drug Toxicity & Efficacy Testing

By End User

• Biotechnology and pharmaceutical industries
• Academic & Research Institutes
• Hospitals and diagnostic centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America